CA2424834A1 - Nogo receptor homologs - Google Patents

Nogo receptor homologs Download PDF

Info

Publication number
CA2424834A1
CA2424834A1 CA002424834A CA2424834A CA2424834A1 CA 2424834 A1 CA2424834 A1 CA 2424834A1 CA 002424834 A CA002424834 A CA 002424834A CA 2424834 A CA2424834 A CA 2424834A CA 2424834 A1 CA2424834 A1 CA 2424834A1
Authority
CA
Canada
Prior art keywords
ngr
polypeptide
seq
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002424834A
Other languages
English (en)
French (fr)
Inventor
Stephen M. Strittmatter
Richard L. Cate
Dinah W. Y. Sah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen MA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2424834A1 publication Critical patent/CA2424834A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002424834A 2000-10-06 2001-10-06 Nogo receptor homologs Abandoned CA2424834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23836100P 2000-10-06 2000-10-06
US60/238,361 2000-10-06
PCT/US2001/031488 WO2002029059A2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Publications (1)

Publication Number Publication Date
CA2424834A1 true CA2424834A1 (en) 2002-04-11

Family

ID=22897532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002424834A Abandoned CA2424834A1 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Country Status (12)

Country Link
US (5) US20030124704A1 (enExample)
EP (1) EP1325130B1 (enExample)
JP (2) JP4465148B2 (enExample)
AT (1) ATE458815T1 (enExample)
AU (2) AU1153902A (enExample)
CA (1) CA2424834A1 (enExample)
DE (1) DE60141409D1 (enExample)
DK (1) DK1325130T3 (enExample)
ES (1) ES2341608T3 (enExample)
NZ (1) NZ525422A (enExample)
PT (1) PT1325130E (enExample)
WO (1) WO2002029059A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
WO2003018631A2 (en) * 2001-08-27 2003-03-06 Novartis Ag Nogo receptor homologues and their use
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
AU2003246254A1 (en) * 2002-07-05 2004-01-23 Shionogi And Co., Ltd. NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF
CA2495121A1 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
EP2902491A1 (en) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO receptor binding protein
EP1623036A4 (en) * 2003-04-04 2007-06-20 Univ Rochester IDENTIFICATION OF NEW NOGO RECEPTORS AND ASSOCIATED METHODS
MXPA05011100A (es) * 2003-04-16 2006-04-18 Univ Yale Antagonistas de receptor nogo para el tratamiento de condiciones que comprenden placas amiloideas.
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
EP1695061A4 (en) * 2003-12-16 2008-02-20 Childrens Medical Center METHOD OF TREATING NEUROLOGICAL DISORDERS
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
CN1946418A (zh) * 2004-01-30 2007-04-11 比奥根艾迪克Ma公司 利用nogo受体拮抗剂治疗涉及多巴胺能神经元退变的疾病
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
JP2008515804A (ja) * 2004-10-01 2008-05-15 イェール ユニバーシティ Ｎｏｇｏ−Ａポリペプチド断片、改変体Ｎｏｇｏレセプター１ポリペプチドおよびそれらの使用
EP1904091A4 (en) * 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
JP2009505665A (ja) * 2005-08-25 2009-02-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｎｏｇｏ受容体ポリペプチドおよびポリペプチドフラグメント、ならびにそれらの使用
JP5829373B2 (ja) 2006-01-27 2015-12-09 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｎｏｇｏレセプターアンタゴニスト
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
WO2007137303A2 (en) * 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
US20100047232A1 (en) * 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
CN101971034A (zh) * 2007-12-11 2011-02-09 健泰科生物技术公司 神经元再生的调控剂
US8992918B2 (en) 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
CL2009001155A1 (es) * 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US12343748B2 (en) 2021-03-16 2025-07-01 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
US12434252B2 (en) 2022-04-20 2025-10-07 Rain Bird Corporation Full-circle and part-circle rotor sprinkler
US12440855B2 (en) 2022-10-27 2025-10-14 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU652537B2 (en) 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
CA2117889A1 (en) 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO1999007891A1 (en) * 1997-08-05 1999-02-18 Human Genome Sciences, Inc. 90 human secreted proteins
WO2000070050A1 (en) 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1490386B1 (en) 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
JP2002518010A (ja) * 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
EP2264174A3 (en) 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
KR100728405B1 (ko) * 1998-11-06 2007-06-13 더 유니버시티 오브 취리히 Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
EP1135485B1 (en) 1998-12-01 2010-02-17 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20030002292A (ko) 1999-03-08 2003-01-08 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
EP1165784A2 (en) 1999-03-31 2002-01-02 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
AU6394400A (en) 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
AU2575901A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel leucine rich repeat-containing molecules and uses therefor
ES2341842T3 (es) * 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6695956B2 (en) 2000-04-18 2004-02-24 Teijin Limited Oxygen concentrating apparatus
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
WO2003018631A2 (en) 2001-08-27 2003-03-06 Novartis Ag Nogo receptor homologues and their use
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
CA2495121A1 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists

Also Published As

Publication number Publication date
EP1325130B1 (en) 2010-02-24
JP2004528809A (ja) 2004-09-24
US20030124704A1 (en) 2003-07-03
US7173118B2 (en) 2007-02-06
US20090175850A1 (en) 2009-07-09
EP1325130A2 (en) 2003-07-09
WO2002029059A9 (en) 2003-05-15
US20050048520A1 (en) 2005-03-03
NZ525422A (en) 2006-09-29
ATE458815T1 (de) 2010-03-15
US20070104713A1 (en) 2007-05-10
PT1325130E (pt) 2010-05-31
AU2002211539B2 (en) 2007-01-25
AU1153902A (en) 2002-04-15
ES2341608T3 (es) 2010-06-23
WO2002029059A2 (en) 2002-04-11
WO2002029059A3 (en) 2003-01-23
DE60141409D1 (de) 2010-04-08
JP2009100767A (ja) 2009-05-14
DK1325130T3 (da) 2010-05-25
JP4465148B2 (ja) 2010-05-19
US20110129477A1 (en) 2011-06-02
US7456255B2 (en) 2008-11-25

Similar Documents

Publication Publication Date Title
CA2424834A1 (en) Nogo receptor homologs
AU2002211539A1 (en) Nogo receptor homologs
JP4486187B2 (ja) 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US7507542B2 (en) Method for regulating immune function using the FOXP3 protein
EP1572961A2 (en) Actriib fusion polypeptides and uses therefor
AU1575601A (en) G protein-coupled receptors expressed in brain
WO2001070975A1 (fr) Nouveau recepteur d'hormone concentrant la melanine
JP2003512028A (ja) ケモカインレセプター
KR20070011545A (ko) 수용체
US20030170741A1 (en) Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
US20030148951A1 (en) Human EMR2, a G-protein coupled receptor from the EGF_TM7 family
US20020115205A1 (en) Polypeptide
US20020065215A1 (en) Polypeptide
US20040091928A1 (en) G protein-coupled receptors expressed in brain
US20040067553A1 (en) Novel g protein-coupled receptor protein and dna thereof
EP1673436A2 (en) Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof
JP4167868B2 (ja) 新規分泌蛋白質およびそのｄｎａ
US20040005997A1 (en) Methods for identifying compounds for regulating muscle mass of function using amylin receptors
US20020076758A1 (en) Polypeptide
JP2004521612A (ja) ３９残基のヒト結節漏斗状ペプチド
JP2001149072A (ja) 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
WO2002066049A1 (fr) Agents pour changement plasmique
AU2002316743A1 (en) A novel G protein-coupled receptor, GAVE8
EP1448583A2 (en) A novel g protein-coupled receptor, gave8

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued